AbbVie Inc.
ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$288.84−6.05 (-2.05%)
Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%
AbbVie Net Litigation Reserve Charges / Adjustments by Year
Net Litigation Reserve Charges / Adjustments ($M) ($M)
AbbVie Net Litigation Reserve Charges / Adjustments: -$933M in FY2025, down 283.7% from a year earlier.
Latest, FY2025
-933
Period ended Dec 31, 2025
Change on a year earlier
-283.7%
508 in FY2024
History
6 years
Since FY2020
Sources
4
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-20) ↗
Reported in Form 10-Q / 10-K Contingencies Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Litigation Reserve Charges / Adjustments ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -933 | -283.7% | Form 10-K (filed 2026-02-20) ↗ |
| FY2024 | Dec 31, 2024 | 508 | -214.7% | Form 10-K (filed 2026-02-20) ↗ |
| FY2023 | Dec 31, 2023 | -443 | -119.8% | Form 10-K (filed 2026-02-20) ↗ |
| FY2022 | Dec 31, 2022 | 2,243 | +1,276.1% | Form 10-K (filed 2025-02-14) ↗ |
| FY2021 | Dec 31, 2021 | 163 | -625.8% | Form 10-K (filed 2024-02-20) ↗ |
| FY2020 | Dec 31, 2020 | -31 | – | Form 10-K (filed 2023-02-17) ↗ |
Cite this data
StockData. (2026). AbbVie Net Litigation Reserve Charges / Adjustments ($M), annual FY2020–FY2025 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/lit-adj-net
See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.